HDAC9 and non-small cell lung carcinoma: Despite limited single-agent efficacy, few objective responses, and substantial toxicity observed in clinical trials, HDAC inhibitors have demonstrated potential in pre-clinical studies for the treatment of NSCLC [14,15].